The ruling was made by the regulatory body NICE just a few days ago. Today in the British Sunday Newspapers there are some columnists already criticizing the ruling.
The control arm is being treated with the corticosteroid prednisone, and not with placebo, making prednisone in effect a comparator treatment. Corticosteroids like prednisone can increase survival in men with metastatic prostate cancer. If the cabo arm does not have a statistically significant increase in OS compared to patients treated with prednisone alone, this will not be good for cabo.
It is possible that the designers of the trial may have underestimated the beneficial effects of corticosteroids in the treatment of metastatic prostate cancer. Could this hypothesized underestimation of steroid beneficial effect be the reason why we are still awaiting announced results of this trial?
Give me A Break...The comparator arm is Prednisone a $1.00 per month medicine that has been around for 50 years. If cabo can't beat prednisone then maybe cabo shouldn't be allowed to be marketed as a treatment for metastatic prostate cancer and we should move on to something better!
Of course metmab was a monoclonal and cabo is a small molecule. Remember that monoclonals did not work in EGFR mutated NSCLL and the small molecules erlotinib and gefitinib do work. Interesting detailed science.
Can Cabo give an overall survival advantage to men with metastatic hormone refractory prostate cancer treated with Cabo at 60 mg daily compared to men treated with prednisone? We will find out soon.
$4.04 to $4.00 before reversal upward, IMO. I don't think it will go below $4.00 for any length of time.
Poor email with way too much advertising. Essentially nonfunctional with chrome book--possibly by yhoo's choice. Yhoo really should try to do better.